Plamumab 40mg Injection (0.8ml Each)
Marketer
Cipla Ltd
Salt Composition
Adalimumab (40mg)
Overview Plamumab 40mg Injection (0.8ml Each)
Each 0.8ml Plamumab 40mg injection treats diverse inflammatory conditions including ankylosing spondylitis, rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease. It alleviates associated inflammation, pain, and discomfort, enhancing physical capability. Administered by a healthcare provider, this injection requires consistent daily usage for optimal efficacy. Complete the prescribed course, even with symptom improvement. Potential side effects, including headache, sinusitis, rash, upper respiratory infections, and injection site reactions (pain, redness, swelling), should be reported if persistent or worsening. Your physician can offer management strategies. Prior to use, disclose any pre-existing heart, kidney, or liver issues, and all other medications to your doctor. Pregnant or breastfeeding individuals require medical consultation before commencing treatment. A Tata 1mg-managed patient support program operates in India; contact your physician or call (1800-102-1618) for details.
Primary Ingredients of Plamumab 40mg Injection (0.8ml Each)
The provided text is "undefined," therefore no rephrasing is possible.
Uses of Plamumab 40mg Injection (0.8ml Each)
Spondyloarthropathy|Chronic inflammatory arthritis|Psoriatic arthritis|Inflammatory bowel disease|Inflammatory bowel disease
Major Benefits of Plamumab 40mg Injection (0.8ml Each):
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Plamumab 40mg Injection (0.8ml Each):
- Headache
- Sinus inflammation
- Rash
- Upper respiratory tract infection
- Injection site reaction
How to use Plamumab 40mg Injection (0.8ml Each):
Administering this medication will be done by your physician or their assigned nurse; self-medication is strictly prohibited.
How Plamumab 40mg Injection (0.8ml Each) works:
Each 0.8ml Plamumab injection (40mg) inhibits specific inflammatory mediators, thereby mitigating the swelling, redness, and inflammation characteristic of some arthritic conditions.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse interactions between Plamumab 40mg Injection (0.8ml Each) and alcohol consumption.
PregnancySAFE IF PRESCRIBED
The injectable formulation of plamumab (40mg in 0.8ml) is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or no harmful effects on fetal development; nevertheless, clinical data from human studies remain scarce.
Breast feedingSAFE IF PRESCRIBED
The administration of a 40mg Plamumab injection (0.8ml per dose) while breastfeeding is likely safe. Available human data indicate minimal risk to the infant.
DrivingUNSAFE
A single 40mg dose of Plamumab injection (0.8ml) can induce adverse reactions, potentially impairing driving skills. These reactions may include dizziness and blurred vision, thereby affecting the ability to operate a vehicle safely.
KidneyCONSULT YOUR DOCTOR
Data regarding the administration of 40mg Plamumab Injection (0.8ml vials) to individuals with renal impairment is scarce. Physician consultation is advised.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the administration of 40mg Plamumab injections (0.8ml each) to individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Plamumab 40mg Injection (0.8ml Each) :
Should you inadvertently omit a dose of the Plamumab 40mg Injection (0.8ml vial), seek immediate medical advice.
Facts to Know About Plamumab 40mg Injection (0.8ml Each)
| Label | Value |
|---|---|
| Chemical Category | Monoclonal antibody |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
| Behavior Class | Biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) |
3,018 People bought this recently